Minimally Invasive Aesthetic Treatments in Men: A Systematic Review and Meta-Analysis.

Dermatol SurgAug 11, 2026 (epub)
Clinical ResearchPlastic SurgeryDermatology

Aina García Dinnbier, Esmeralda Silva Diaz, Francisca Ibáñez García

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of minimally invasive aesthetic treatments in male patients, analyzing data from 10 studies involving 12,603 participants. The meta-analysis of 5 randomized controlled trials revealed an 85% response rate to botulinum toxin type A for upper facial wrinkles, indicating effective treatment outcomes.

Key findings

  • The response rate to botulinum toxin type A for upper facial wrinkles was 85% (95% CI: 0.74-0.97).
  • Adverse events from treatments were minor and transient, with an incidence of 16% (95% CI: 0.10-0.23).
  • Men often required higher product volumes for neuromodulators and fillers compared to women.

Why it matters

Understanding the specific needs and outcomes of male patients in aesthetic treatments can help clinicians tailor their approaches, ensuring effective and safe interventions that meet this growing demographic's expectations.

Source

PubMed · PMID 42574235

Published in Dermatol Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Plastic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.